Literature DB >> 8103295

High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma.

E Cesarman1, G Inghirami, A Chadburn, D M Knowles.   

Abstract

Strong immunohistochemical reactivity for p53 tumor suppressor gene product has been reported in a variety of different human malignancies including CD30- (Ki-1) positive anaplastic large cell lymphoma (ALCL). Although high levels of p53 protein have been interpreted as abnormal, rapidly proliferating benign and neoplastic lymphoid cells may have increased p53 expression in the absence of structural alterations. On the other hand, mutations in the p53 gene can lead to a lack of p53 protein production. Structural alterations of the p53 gene have not been documented in cases of ALCL and the mechanism for an abnormal pattern of p53 expression in these lymphomas has not been elucidated. Therefore, to determine whether an altered pattern of p53 expression correlates with mutations in the p53 locus in ALCL, we analyzed the expression of p53 protein immunohistochemically, compared it with the proliferation index using monoclonal antibody Ki-67, and assessed the presence of mutations in exons 5 though 9 of the p53 gene using a single-strand conformation polymorphism assay in a panel of 17 ALCLs. Furthermore, we studied the presence of allelic deletions of chromosome 17p by restriction fragment length polymorphism analysis. We found significant levels of p53 protein expression in 12 of the 15 cases studied, but identified mutations in only one of 17 cases. An allelic deletion in chromosome 17p was identified only in the one case containing a mutated p53 gene. Whereas the case containing structural alterations in the p53 gene did have strong p53 immunoreactivity, 11 cases that lacked p53 mutations in the regions examined also had significant levels of p53. Thus, our studies indicate that strong immunohistochemical reactivity for p53 is not a reliable indicator of the presence of structural alterations of p53 gene exons 5 through 9 in ALCL.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8103295      PMCID: PMC1887225     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  54 in total

Review 1.  p53 function and dysfunction.

Authors:  B Vogelstein; K W Kinzler
Journal:  Cell       Date:  1992-08-21       Impact factor: 41.582

2.  Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression.

Authors:  L Banks; G Matlashewski; L Crawford
Journal:  Eur J Biochem       Date:  1986-09-15

3.  The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13).

Authors:  O W McBride; D Merry; D Givol
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

4.  A hypervariable RFLP on chromosome 17p13 is defined by an arbitrary single copy probe p144-D6 [HGM9 No. D17S34].

Authors:  S Kondoleon; H Vissing; X Y Luo; R E Magenis; J Kellogg; M Litt
Journal:  Nucleic Acids Res       Date:  1987-12-23       Impact factor: 16.971

5.  Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53.

Authors:  N C Reich; M Oren; A J Levine
Journal:  Mol Cell Biol       Date:  1983-12       Impact factor: 4.272

6.  Human p53 gene localized to short arm of chromosome 17.

Authors:  C Miller; T Mohandas; D Wolf; M Prokocimer; V Rotter; H P Koeffler
Journal:  Nature       Date:  1986 Feb 27-Mar 5       Impact factor: 49.962

7.  Increased expression of p53 protein in human leukemia cells.

Authors:  H P Koeffler; C Miller; M A Nicolson; J Ranyard; R A Bosselman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

8.  Expression of p53 in human leukemia and lymphoma.

Authors:  M Prokocimer; M Shaklai; H B Bassat; D Wolf; N Goldfinger; V Rotter
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

9.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.

Authors:  H Stein; D Y Mason; J Gerdes; N O'Connor; J Wainscoat; G Pallesen; K Gatter; B Falini; G Delsol; H Lemke
Journal:  Blood       Date:  1985-10       Impact factor: 22.113

10.  Lymphoid tumors displaying rearrangements of both immunoglobulin and T cell receptor genes.

Authors:  P G Pelicci; D M Knowles; R Dalla Favera
Journal:  J Exp Med       Date:  1985-09-01       Impact factor: 14.307

View more
  18 in total

1.  Significance of Wet Autoclave Pretreatment in Immunohistochemistry.

Authors:  József Piffkó; Dietmar Öfner; Rita Dreier; Werner Böcker; Kurt Werner
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

2.  One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes.

Authors:  Karl Sotlar; Luis Escribano; Olfert Landt; Stefanie Möhrle; Sonia Herrero; Antonio Torrelo; Ulrich Lass; Hans-Peter Horny; Burkhard Bültmann
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

3.  Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.

Authors:  Ken H Young; Dennis D Weisenburger; Bhavana J Dave; Lynette Smith; Warren Sanger; Javeed Iqbal; Elias Campo; Jan Delabie; Randy D Gascoyne; German Ott; Lisa Rimsza; H Konrad Müller-Hermelink; Elaine S Jaffe; Andreas Rosenwald; Louis M Staudt; Wing C Chan; Timothy C Greiner
Journal:  Blood       Date:  2007-09-19       Impact factor: 22.113

4.  Detection of p53 in inflammatory tissue and lymphocytes using immunohistology and flow cytometry: a critical comment.

Authors:  A Nickels; H Selter; M Pfreundschuh; M Montenarh; B Koch
Journal:  J Clin Pathol       Date:  1997-08       Impact factor: 3.411

5.  Alterations in the tumor suppressor genes p53, RB, p16/MTS1, and p15/MTS2 in human pancreatic cancer and hepatoma cell lines.

Authors:  M Kaino
Journal:  J Gastroenterol       Date:  1997-02       Impact factor: 7.527

6.  Germ cell tumors of the testis overexpress wild-type p53.

Authors:  L Guillou; A Estreicher; P Chaubert; J Hurlimann; A M Kurt; G Metthez; R Iggo; A C Gray; P Jichlinski; H J Leisinger; J Benhattar
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

7.  p53 protein expression in non-Hodgkin's lymphoma. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.

Authors:  M Tzardi; C Kouvidou; I Panayiotides; K Stefanaki; D Rontogianni; E Zois; K Koutsoubi; G Eliopoulos; G Delides; P Kanavaros
Journal:  Clin Mol Pathol       Date:  1996-10

8.  Epstein-Barr virus-associated anaplastic large cell variant of diffuse large B-cell-type non-Hodgkin's lymphoma with concurrent p53 protein expression.

Authors:  Yuko Hirose; Yasufumi Masaki; Kumiko Shimoyama; Toshihiro Fukushima; Hiroshi Kawabata; Noriyoshi Ogawa; Yuji Wano; Susumu Sugai
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

9.  Pigmentation, Melanocyte Colonization, and p53 Status in Basal Cell Carcinoma.

Authors:  Lídia M Frey; Roland Houben; Eva-B Bröcker
Journal:  J Skin Cancer       Date:  2010-09-29

10.  p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia.

Authors:  M Kitagawa; S Yoshida; T Kuwata; T Tanizawa; R Kamiyama
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.